Implementation of Bridging Study-Taiwan's Experience
Implementation of Bridging Study-Taiwans Experience Meir-Chyun Tzou, Ph.D. Senior Officer, and Director of Section III, Bureau of Pharmaceutical Affairs Department of Health, The Executive Yuan Taipei, Taiwan, R.O.C. Outline Health Organization and the Drug Regulatory Agency Changing Environment of Clinical Trial in Taiwan Regulatory Strategies for Implementation of Bridging Study Current Status of Bridging Study Evaluation APEC Joint Research Project on Bridging Study
Organization of the Department of Health, the Executive Yuan, ROC Secretary General Minister Deputy/Vice Minister Specialist-General Counselor Bureau of Medical Affairs National Bureau of Controlled Drugs Bureau of Pharmaceutical Affairs Center for Disease Control
Bureau of Food Sanitation National Institute of Preventive Medicine Bureau of Health Promotion National laboratories of Food and Drugs Bureau of Health Planning Office of Secretariat Office of Personnel Affairs National Quarantine Service Bureau of National
Health Insurence Committee on Chinese Medicine and Pharmacy Office of Anticorruption NHI Supervisory Committee Office of Accounting NHI Health Care Cost Arbitration Committee Office of Statistics National Health Research Institutes Center for Drug Evaluation
Changing Environmental of Clinical Trial in Taiwan Regulations Update for Clinical Trials Local clinical trial required for New Drug Re gistration since 1993 GCP guidelines implemented in 1997 GCP inspections for INDs and NDAs in 1997 Adverse Drug Reporting system in 1998 Guidances for clinical trials Impact on New Drug Development in Taiwan
Local clinical trials -Improve new drug R & D in Taiwan. -Facilitate development of Biotech / Pharmaceutical Industry Global Environment / Trends International Harmonization for New Drug Registration : ICH Trade Liberalization : WTO Accession Biotech / Pharmaceutical Industry Promotion Plan Consolidating Infrastructure for New Drug Clinical Trials in Taiwan Improving quality and efficiency of review
process for clinical trials Promoting early phase clinical trials in Taiwan Establishing Center for clinical study in Asia Pacific Promoting Biotech-pharmaceutical Industry Consolidating Infrastructure for New Drug Clinical Trials in Taiwan (1) Improving quality and efficiency of review process for clinical trials
Reinforcement of GCP inspection Guidances for clinical trials Establishment of the Center for Drug Evaluation (CD E) in 1998 -full time review team Parallel review process of IRBs and DOH Establishment of Joint-IRB Deregulation and streamlining the review process for clinical trials Center for Drug Evaluation -expert review team for clinical trials and NDAs Consultation C.D.E. Advisory Board (Review Committee)
Advice Consult Applicant Application Approval D.O.H. (BPA) DRF BPA: Bureau of Pharmaceutical Affairs; CDE:Center for Drug Evaluation DOH: Department of Health DRF: Drug Relief Foundation Parallel Review Process of IRB/JIRB and DOH Conducting
Efficiency-Speedup in Review Time in Taiwan for New Drugs (Day) 300 306 1997 250 1998 200 150 137 1999 123
112 2000.1-2000.6 89 100 63 50 52 32 0 Imported New Drug Application
Clinical Trial Protocols 2000.7-Present Consolidating Infrastructure for New Drug Clinical Trials in Taiwan (2) Promoting early phase clinical trials in Taiwan Establishing general clinical research centers (GCRC) -improving the quality and performance of the CRC. Establishing insurance and ADR reporting system for clinical trials Establishing central lab. (clinical pathology unit) -assuring the quality of clinical laboratory Regulatory reform in local clinical trial-bridging study Regulatory Strategies for Implementation of Bridging Study
Regulatory Reform in Local Clinical Trial Bridging Study Before An approved local clinical trial study report is required for the new drug application in Taiwan --July 7 Announcement in 1993. Disadvantage: - A sample size of 40 as required would be difficult to demonstrate significant importance clinically or statistically - The study design of the local trial usually only repeated a study that has been done in the foreign countries but in a smaller sample size The study has not been designed based on the Regulatory Reform in Local Clinical Trial Bridging Study After
Bridging Study (Double Twelve Announcement, 2000) -Follow ICH E5 guidance Advantage: - To avoid repeating unnecessary clinical study - Conducting, necessary, meaningful clinical study based on differences of disease, ethnic differences etc, and the results of study, a dosage adjustment can be done for the locals Strategies for Implementation of Bridging Study To follow closely the spirit of the ICH E5
guidance To establish a sound and practical consultation and evaluation process encourage sponsor to submit complete clinical data package for the evaluation of bridging study before new drug application guidance and Q & A data base self-evaluation checking list consultation process assessment scheme Double Twelve Announcement for Bridging Studies Dec. 12, 2000 Effective on January 1, 2001 One-year of transition period
-Local clinical trial bridging study In accordance with ICH E5 guidance Procedure of consultation and evaluation of bridging study Considerations for Assessing the Necessity of a Bridging Study ( 1of 4 ) Submit relevant documents Does the drug meet DOH requirements for waiving YES according to DOH a bridging study and also the criteria for exempting requirements and request submission of information for ethnic consideration?(1) for waiving bridging studies NO Does the submitted preclinical and clinical data package meet the regulatory requirements (ICH E5 and DOH guidance on clinical trials)?(2) NO
Amendment YES NO Does the package include clinical data of Asian populations?(3) Is the medicine insensitive to both intrinsic and extrinsic factors? efficacy and safety insignificant? (See ICH E5 guidelines) YES YES NO Considerations for Assessing the Necessity of a Bridging Study
( 2 of 4 ) Does the package include clinical data of Asian populations?(3) NO YES YES Have any early phase trials or global clinical trials that meet the YES DOH requirements of bridging studies been conducted in Taiwan? NO Is it reasonable to extrapolate from foreign clinical data that the medicine is insensitive to both intrinsic and extrinsic factors in Asians(3) and that its clinical differences in efficacy and safety are acceptable?(See ICH E5 guidelines)
NO Is the medicine insensitive to both intrinsic and extrinsic factors? Are the clinical differences in efficacy and safety insignificant? (See ICH E5 guidelines) No bridging study required(4) NO Based on the result of evaluation, an appropriately designed protocol of a bridging study should be submitted to DOH for approval(5) YES No bridging study required(4) Considerations for Assessing the Necessity of a Bridgi
ng Study ( 3 of 4 ) Is it reasonable to extrapolate from foreign clinical data that the medicine is insensitive to both intrinsic and extrinsic factors in Asians(3) and that its clinical differences in efficacy and safety are acceptable?(See ICH E5 guidelines) YES No bridging study required(4) NO Is it reasonable to extrapolate from foreign clinical data that the concentration (dose)-response relationship is similar between foreign and Asian populations(3)? NO Is PK and/or PD data of Asian
populations(3) available for estimating dosage or predicting efficacy? YES NO YES Based on the result of evaluation, an appropriately designed protocol of a bridging study should be submitted to DOH for approval.(5) Considerations for Assessing the Necessity of a Bridgi ng Study ( 4 of 4 ) Is PK and/or PD data of Asian populations(3) available for estimating dosage or predicting efficacy? YES
NO Based on the result of evaluation, an appropriately designed protocol of a bridging study should be submitted to DOH for approval.(5) Using available data for dose determination Apply for waiving bridging studies with reference to DOH announcements of waiving clinical trials. If the drug falls within the category that requires submission of information proving no e xistence of ethnic differences, it should be evaluated following this flowchart after the one year phase-in period. (2) Under circumstances when evidence indicating potential intrinsic/extrinsic differences betwee n Chinese and other Asian populations, a bridging study in Chinese population is a must. (3) A bridging study will be required when there exists any safety concern. (4) 1 Under circumstances when evidence indicating potential intrinsic/extrinsic differences betwe en Chinese and other Asian populations, a bridging study in Chinese population is a must.
(5) A bridging study can be a PK and/or PD study or any clinical study that can demonstrate the efficacy and safety of the medicine. (1) Bridging Study Evaluation --Current Status-18 8 7 No.of Bridging Study Evaluation Applications in 2001 6 5 5 4 3 3
3 3 2 2 1 1 0 0 Jan. 0 Feb. Mar. Apr. May Jun. 1 Jul.
Aug. Sep. Total Bridging Study Evaluation --Current Status- Bridging study evaluation : 18 cases applied. (2001-present) 8/11 (73%) waived (including 4 without complete Asian data). Out of 3 not waived, 1 has safety concern, 2 did not have enough information. Impact of Bridging Study on Clinical Trials Promoting early phase / global clinical trials in Taiwan Conducting necessary, meaningful clinical study based on scientific and medical circumstances (intrinsic/ extrinsic factors)
Establish Network of Pharmaceutical Regulatory Science - APEC Joint Research Project Objectives: To establish an APEC network of pharmaceutical regulatory science To promote regulatory consensus through regional educational seminar, or APEC conference To develop a sound and practical methodology for implementing bridging study in accordance with ICH E5 by APEC members for the global new drug development Establish Network of Pharmaceutical Regulatory Science - APEC Joint Research Project 1999 At the 17th APEC ISTWG Meeting, all of the APEC economies have reached consensus on this project proposed and sponsored by Chinese Taipei and co-sponsored by Singapore, Philippines, Mexico, Malaysia,
and Australia. 2000 The 1st workshop was held in Taipei. 2001 The 2001 symposium was held in Taipei. The 2001 Symposium on APEC Network of Pharmaceutical Regulatory Science- APEC Joint Research Project on Bridging Study Conclusion(1) 1. Bridging justification should be based on sound science and intrinsic /extrinsic factors, not based on citizenship and nationality. 2. The regulatory agency should consider existing data and various factors (scientific and medical
circumstances ) for drug approval. 3. Criteria for the similarity of efficacy,safety and quality between regions is needed. The 2001 Symposium on APEC Network of Pharmaceutical Regulatory Science- APEC Joint Research Project on Bridging Study Conclusion(2) 4. Bridging: Multi-directional Input and output between ICH/ Non ICH region should be involved 5. ICH E5- Identifying the questions from APEC region, elaboration/supplement is needed. 6. Consolidate the networking of pharmaceutical regulatory science within APEC is obviously.
Detailed analysis (please refer to your textbook) shows that T 2 = T 1. e where is the coefficient of static friction between the belt and the surface. Be sure to use radians when using this formula!!If the belt slips...
A FROM GEESE AUTHOR UNKNOWN ♫ Turn on your speakers! CLICK TO ADVANCE SLIDES Have you ever wondered why migrating geese fly in a V formation? As with most animal behavior, God had a good reason for including that in...
Structure of Carboxylic Acids. Depending on whether an R or an Ar. residue is attached to the carboxyl group; Carboxylic acids are classified as aliphatic or aromatic.. Aliphatic Carboxylic Acids. Aromatic Carboxylic Acids. Fatty acids. Long straight-chain carboxylic acids with...
Links to Corporate Strategies? Balance Sheet is just a snapshot in time but….. Needs to be linked to future plans and strategies:-Corporate Aims and Objectives. Medium-Term Financial Plans. Capital Plans and Strategies. Asset Management Plans. Reserves Strategy. Effective treasury management...
TexPoint fonts used in EMF. Read the TexPoint manual before you delete this box.: AAA + * Unsupervised learning Supervised learning Predict target value ("y") given features ("x") Unsupervised learning Understand patterns of data (just "x") Useful for many reasons...
Ready to download the document? Go ahead and hit continue!